cyrilzakka/clinical-trials huggingface dataset:
The Effect of the Oslo Sports Trauma Research Center (OSTRC) Injury Prevention Exercises Reducing Injuries Rate Among Athletes.

The Oslo Sports Trauma Research Center (OSTRC) was established in May 2000 at the Norwegian School of Sport Sciences.The OSTRC aims to prevent injuries and other health problems related to sports. The majority of the research conducted at OSTRC involves elite sports.

The purpose of this study is to investigate the effect of the Oslo Sports Trauma Research Center (OSTRC) Injury Prevention Program in reducing injuries among athletes.

Hypothesis: that Oslo Sports Trauma Research Center (OSTRC) Injury Prevention Program has a beneficial effect in terms of injury prevention.

The purpose of this study is to investigate the effect of the Oslo Sports Trauma Research Center (OSTRC) Injury Prevention Program in reducing injuries among athletes.

Study type Interventional Description of intervention(s) / exposure: The intervention group will be instructed to include the Oslo Sports Trauma Research Center (OSTRC) Injury Prevention Program as a warm up before training session (3 times per week) during one season (6 months).

Group sessions will be administered by an exercise physiologist and/ or athletic trainer and/ or soccer coaches and/ or strength and conditioning specialists and/ or physiotherapist.

Session attendance checklists will be used to assess or monitor adherence to the intervention.

Comparator / control treatment The control group will practice their usual warm up.

Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.

Eligibility Criteria:
Inclusion Criteria:

* Healthy
* Amateur Athletes
* Training at least three times per week

Exclusion Criteria:

* History of lower extremity injury requiring medical attention in the past 6 months
* Systemic diseases
* Cardiovascular disease
* Neurological disorders
* Bone fractures
* Surgery in the previous year.
Midodrine, Octreotide and Albumin: Impact on Renal Function of Patients With Liver Cirrhosis and Renal Failure

The aim of this study is to evaluate the treatment with midodrine, octreotide and albumin during 12 weeks in patients with hepatorenal syndrome. Fifteen patients will be enrolled and followed during 16 weeks. The effects on renal function will be evaluated 12 and 16 weeks after the beginning of the treatment by isotopic evidence and biochemist determinations. Also it will be evaluated arterial pressure and determination of vasoactive hormones (plasma renin, aldosterone and norepinephrine).


Eligibility Criteria:
Inclusion Criteria:

* Age between 18 and 80 years
* Cirrhosis of the liver defined by clinical, biochemical or histological
* Functional renal failure with serum creatinine greater than 1.2 mg / dl and less than 2.5 mg / dl.
* That, properly informed, give their consent to participate in the study and undergo tests and examinations that entails
* Women of childbearing potential: pregnancy test negative serum or urine, and acceptance of use of adequate contraception since at least 14 days prior to the first dose of study drug until 14 days after the last dose

Exclusion Criteria:

* Pregnant women, nursing mothers, or those who intend to become pregnant during the study period
* Systolic blood pressure ≥ 150 mmHg and / or diastolic blood pressure ≥ 90 mmHg
* Previous treatment with transjugular intrahepatic portosystemic shunt (TIPS) or surgical portosystemic shunts
* Use of antibiotics in the seven days prior to inclusion in the study except for prophylactic (ie. prophylaxis of spontaneous bacterial peritonitis)
* Cardiac or respiratory failure
* Positive for human immunodeficiency virus
* Urinary retention
* Ischemic heart disease or peripheral vascular disease.
* Narrow Angle Glaucoma
* Cerebrovascular occlusions
* Aortic Aneurysm
* Thyrotoxicosis
* Pheochromocytoma
AccuIMR Predicts Microvascular Obstruction and Infarct Size in STEMI Patients

In this study, we aimed to investigate the clinical significance of the angiography-based IMR calculation method (AccuIMR) and its prognostic assessment capability by evaluating the concordance or discordance between AccuIMR values and cardiac magnetic resonance (CMR) results.


Eligibility Criteria:
Inclusion Criteria:

* (1) STEMI patients who underwent PCI within 12 hours of symptom onset.
* (2) coronary microvascular function was assessed using contrast-enhanced CMR after PCI.

Exclusion Criteria:

* (1) Suboptimal coronary angiographic images, including inadequate contrast opacification, unsatisfactory projection view, and severe overlap or distortion of the target vessel.
* (2) Lacking two angiographic projections separated by at least 25° apart post-PCI.
* (3) Inadequate CMR image quality
Study of the Impact of the Minimum Inhibitory Concentration and Susceptible Cut-off Points (CLSI, EUCAST, and Pharmacokinetics/Pharmacodynamics)in Prognosis of Bacteremia by Enterobacteriaceae

Provide scientific and validated data to help International Authorities to set susceptible to antibiotics cut-off points in bacteremia by Enterobacteriaceae


Eligibility Criteria:
Inclusion Criteria:

* \>17 years old
* Clinically significant bacteremia
* Have received treatment fulfilling all this criteria:

  1. Treated with an only active antibiotic with enterobacteria (association with vancomycin, linezolid, daptomycin, metronidazole or clindamycin) between: cefotaxime, ceftriaxone, ceftazidime, cefepime, amoxicillin/clavulanic, piperacillin/tazobactam, ertapenem, imipenem, meropenem, ciprofloxacin or levofloxacin
  2. First antibiotic dose was administered during the first 12 hours after the time of sampling
  3. The antibiotic dosage was at least the advised amount in the summary of product characteristics to patient renal function
  4. The same antibiotic has been administered during at least 48 hours.

     Exclusion Criteria:
The Prevalence of Autoimmune Antibodies in Patients with Type 2 Diabetes Managed by Endocrinology Vs. Primary Care

The purpose of this study is to assess the levels of autoimmune markers of diabetes in those with a type 2 diabetes diagnosis.

Autoimmune markers can appear when the body uses its natural defense system to mistakenly attack the patient's own cells because it cannot tell the difference between the patient and foreign cells. The study investigators want to determine if there are any differences in these marker levels when comparing patients who are managed by their primary care provider and patients managed by endocrinology. Patients will be asked to come in for a blood draw. This sample will be used for autoimmune antibody testing. An antibody is a protein in the blood that is made to find and respond to a specific antigen. An antigen is something that triggers the body to have an immune response. Patient participation in the research study will last for the duration of one visit to the clinic for informed consent and a blood draw.

The clinical implications of detecting this type of diabetes can be profound, as it can identify patients who are at risk of becoming insulin dependent in the near future, and therefore may require a change in diabetes management to avoid adverse outcomes. In addition, identifying these patients may also open up the door for treatments directed at stopping the complete autoimmune destruction of insulin producing cells, potentially delaying or avoiding the need for insulin dependency.

The study team presumes that autoimmune markers of diabetes will be detected in patients with a diagnosis of type 2 diabetes and the prevalence of these markers will be higher among patients managed by endocrinology. The population of patients found to have detectable autoimmune markers of diabetes will differ from the population of patients without these markers. The population of patients managed by endocrinology that are found to have detectable autoimmune markers of diabetes will differ from the population of patients managed by primary care. The population of patients with more than 1 autoimmune antibody are more likely to require insulin therapy.

Eligibility Criteria:
Inclusion Criteria:

* Language: English
* Age: ≥ 18
* Type 2 diabetes
* Ability to provide informed consent before any trial-related activities. Trial-related activities are any procedure that would not have been performed during normal management of the subject.

Exclusion Criteria:

* Patients with a diagnosis of T1D or LADA in their problem list
* Patients with an encounter diagnosis for T1D or LADA
* Mental incapacity or language barrier (non-English speaking)
Opioid-Free Orthopaedics

The goal of this investigation is to compare effectiveness of this multimodal regimen at controlling postoperative pain with and without the use of opioid medications.

Prolonged opioid usage after orthopaedic surgery is an important consideration for both the opioid epidemic and postoperative outcomes. The investigators have developed a multimodal pain control regimen designed to decrease or even potentially eliminate the need for opioids after an orthopedic procedure. This is a prospective double blinded randomized controlled trial utilizing a multimodal pain regimen consisting of education and our standard multimodal pain control regimen. Then, the plan is to randomize patients to receive either encapsulated opioids or placebo. The team will assess patient's pain levels, satisfaction, opioid usage, side effects, patient reported outcomes, and complications. This study will serve as a foundation for future opioid-free surgeries and investigations, while helping to identify patients and factors at risk for prolonged opioid usage postoperatively.

Eligibility Criteria:
Inclusion Criteria:

* Any patient with advanced arthritis undergoing a total joint replacement (e.g. total shoulder arthroplasty, anatomic or reverse), in the primary setting.
* Any patient undergoing an orthopaedic procedure or surgery of their finger, hand, wrist, forearm, or elbow
* Any patient undergoing an orthopaedic procedure or surgery for their hip, knee, ankle or foot
* Patients who have exhausted 3+ months of nonoperative treatment to include activity modifications, optional corticosteroid injections, and physical therapy.
* Patients over the age of 18 years old that are willing to participate in the study and mentally capable to consent

Exclusion Criteria:

* Patients with concurrent and significant injuries to other bones or organs, local infections, history of alcohol or medical abuse, preoperative opioid use within 3 months of the surgery, advanced renal or liver disease, contraindication to receiving a nerve block, uncontrolled diabetes mellitus (HbA1C \>9.0), or if a prior gastric ulcer precludes Aspirin and anti-inflammatory medications.i. Prior to inclusion, the patient will undergo blood testing to evaluate both kidney and liver function, including estimated glomerular filtration rate (GFR) as well as alanine aminotransferase (ALT) and aspartate aminotransferase (AST).
* Workman's compensation status, minors, vulnerable subjects, women who are pregnant, or those who are not willing to consent to participate in the study.
* Patients who, in the opinion of the investigator, may be non-compliant with study schedules or procedures
Composite Plug Vs D-PTFE Membrane in Socket Preservation

The aim of the current study is to compare the effect socket sealing with flowable resin composite compared to dense polytetrafluoroethylene membrane after filling the extraction site with xenograft particles in terms of soft and hard tissue changes, procedural time, post operative pain, patients' satisfaction, and cost effectiveness.

Implant placement has become the gold standard for replacing missing teeth. One of the biggest challenges present when placing implants is the lack of sufficient bone dimensions. This deficiency may be a common finding due to the process of post extraction remodeling where both bone height and width are reduced, complicating implant placement. As a result, several procedures have been suggested to address this issue. Socket preservation is one of the most implemented procedures used today to limit the amount of bone lost during post extraction remodeling. The current study was designed to compare the effectiveness of using flowable composite resin for socket sealing as an alternative to using d-PTFE membranes, bypassing the added time, cost and trauma needed for tunnel preparation and membrane tucking.

Eligibility Criteria:
Inclusion Criteria:

* Patients having single non-adjacent hopeless maxillary tooth in the esthetic zone that are indicated for extraction.
* Patients with healthy systemic condition.
* Patients aged from 20 to 70 years old.
* Good oral hygiene.
* Accepts 4 months follow-up period (cooperative patients).

Exclusion Criteria:

* Systemic diseases or medications that might affect bone metabolism, increase surgical risk or complicate post-operative healing.
* Previous bone augmentation to implant site.
* Untreated periodontal diseases.
* Para-functional habits such as bruxism and clenching.
* History of radiation therapy to the head and neck.
* Heavy smokers (≥ 10 cigarettes per day).
* Pregnant or lactating females.
* Alcoholism or drug abuse.
* Psychiatric problems.
Eliminating Breast Surgery for Breast Cancer Patients With Clinical Complete Response to Neoadjuvant Systemic Therapy

Phase II multicenter prospective study on the safety of eliminating surgery for triple negative or HER2 positive breast cancer patients with clinical response to neoadjuvant radiotherapy and neoadjuvant chemotherapy.

The main purpose: To explore the safety of eliminating surgery for triple negative or HER2 positive breast cancer patients with clinical response to neoadjuvant chemoradiotherapy. Secondary study objective: To explore predictive molecular biomarkers of response to neoadjuvant chemoradiotherapy and investigate whether ctDNA can predict pCR or survival outcome.

Primary endpoint: 5-year event-free survival (5-year EFS). Secondary end points: Whether combined neoadjuvant chemoradiotherapy can improve breast pathological complete response rate (bpCR: ypT0), overall survival (OS), patient-reported outcomes (PROs) and safety

Eligibility Criteria:
Inclusion Criteria:

* Female initial treatment patients aged ≥ 18 years and ≤ 70 years old
* ECOG score 0-1
* Clinical T1-2N0 HER2 positive ( HR negative HER2 IHC score of 3+, or 2+and ISH test positive) or triple negative invasive breast cancer
* Left ventricular ejection fraction (LVEF) ≥ 50%
* 12 lead electrocardiogram: QT interval (QTcF) corrected by Fridericia method for females\<470ms
* The functional level of the main organs must meet the following requirements: blood routine: ANC ≥ 1.5 × 109/L# PLT≥90 × 109/L# Hb≥90 g/L#Blood biochemistry: TBIL ≤ 2.5 × ULN# ALT and AST ≤ 2.5 × ULN# BUN and Cr ≤ 1.5 × ULN#
* For female subjects who have not undergone menopause or surgical sterilization, during the treatment period and during the study treatment
* Agree to abstain or use effective contraceptive methods for at least 2 months after the next administration; .Volunteer to join this study, sign informed consent, have good compliance, and be willing to cooperate with follow-up.

Exclusion Criteria:

* Inflammatory breast cancer
* Metastatic tumor
* Previous or concurrent malignant tumors, whose natural history or treatment may interfere with the safety of the research protocol.
* Active infections that require systemic treatment
* Has used any medication in this study within 14 days prior to enrollment
* Major surgery (excluding biopsy) performed within 14 days before enrollment
Metformin for the Treatment of Diabetes in Pregnancy

The purpose of this study is to determine whether metformin is effective and safe in the treatment of diabetes in pregnancy.


Eligibility Criteria:
Inclusion Criteria:

* pregnant women
* GDM A2
* diabetes mellitus type 2
* singleton pregnancy

Exclusion Criteria:

* diabetic nephropathy or proliferative retinopathy
* cannot swallow tablets
Attention, Teleconferencing and Social Anxiety

This study involves completing some online assessments and an intervention for social anxiety that all involve interactions with other people on a teleconferencing call.


Eligibility Criteria:
Inclusion Criteria:

* Age 18-75
* Fluent in English because the data collection materials have not yet been standardized in other languages
* Having access to a computer with a webcam and ability to record audio
* Personal Report of Communication Apprehension \> 80
* Leibowitz Social Anxiety Scale \> 30
* Meets DSM-5 Criteria for Social Anxiety Disorder

Exclusion Criteria:

* Significant visual impairment precluding the use of the eye tracking equipment
* Current, or history of bipolar disorder; current, or history of psychosis
The Impact of Adverse Events, Produced by Antibodies Conjugates, on Quality of Life in Patients With Metastatic Breast Cancer: Multicentric, Observational Study (EVA).

The study stems from the need to detect adverse events arising after the administration of Antibody-Drug Conjugates (ADCs) used in the treatment of metastatic breast cancer in a real life context and to correlate the same with the quality of life reported by patients.

The study stems from the need to detect adverse events arising after the administration of ADCs used in the treatment of metastatic breast cancer in a real life context and to correlate the same with the quality of life reported by patients.Through the findings of toxicities related to the ADCs, it will be possible to highlight which are the issues that most affect patients undergoing these cancer treatments. The analysis of the data collected will also make it possible to highlight any toxicities not yet considered or/and of new onset. In addition useful elements may emerge from responses to the quality of life questionnaire, to cope with the difficulties expressed by patients regarding daily life activities, social relations, work and family. Such contributions will be fundamental to the construction of integrated care pathways, the aim of which is to involve a specialized nurse as part of a multidisciplinary team.

Eligibility Criteria:
Inclusion Criteria:

* Female gender;
* Age ≥ 18 years;
* Signature of consent to participate in the study and to the processing of personal data (Privacy);
* Diagnosis of stage IV breast cancer;
* Systemic treatment with T-DM1, T-DXD or SG as monotherapy;
* Absence of cognitive decline, expressed by a score greater than or equal to 4 on the Six Item Screener questionnaire;
* Good understanding of the Italian language;
* Willingness and ability to adhere to scheduled visits, treatment plan, laboratory tests and study procedures.

Exclusion Criteria:

* All patients who do not meet the above criteria will be excluded from the study.
Influence of Kinesio Tapping on Quadriceps Muscle Peak Torque and Bioelectrical Activity After Meniscectomy

A Pretest post-test control group design will be used to investigate the effect of kinesio taping on electrical activity and peak torque of the quadriceps femoris muscle during concentric and eccentric contraction after arthroscopic partial meniscectomy (APM) surgery.

Fifty patients after APM of any knee of both sexes will participate in this study after signing a written informed consent form approved.

from the ethical committee of Jazan University. They are selected according to the following Inclusion criteria:

1. All performed APM only without any other knee injury.
2. Finished the period of hospital stay (6-8 weeks)
3. Their age ranged from 20-40.
4. Their Body mass index ranged from 20-24.9 kg/m². 2- The subjects will be excluded from the study if they had one of th e following exclusion criteria: a- Knee or quadriceps disorders preventing physical stress. b- Subjects with cardiovascular or neurological problems. c- Smokers. d- Heavy caffeine intake subjects. 3- The subjects will be randomly assigned into two groups of equal numbers. Group A (Study) consisted of 66 subjects who will receive kinesio-taping from origin to insertion on the superficial muscles of the Quadriceps femoris (QF) (Vastus Medialis (VM), Vastus Lateralis (VL), Rectus Femoris (RF)). - Group B (Control) consisted of 66 subjects who will receive a placebo kinesio-taping across quadriceps. Anthropometric measures including "weight and height" and body. mass index (BMI) will be measured for all subjects in the first meeting before starting the evaluative procedures. All subjects were asked to shave the hair of their thigh before starting the evaluative procedure using blades, which was essential to prevent artifact during EMG evaluation and to facilitate the adherence of the tape to the skin. Bioelectrical activity and peak torque of quadriceps muscle of the lower extremity that had APM will be measured. The evaluation will be carried out before tapping, and then after the application of tapping for 10 minutes.

Eligibility Criteria:
Inclusion Criteria:

1. Clinical diagnosis only with arthroscopic partial meniscectomy
2. Must be finished a period of hospital stay (6-8 weeks)
3. Must have body mass index ranged from 20-24.9 kg/m².

Exclusion Criteria:

a. Knee or quadriceps disorders preventing physical stress. b- Cardiovascular or neurological problems. c- Smokers d- Heavy caffeine intake subjects.
Effect of CPAP vs Control on Nocturnal Dipping in Normotensive Patients With Obstructive Sleep Apnea

This is an open-label, parallel, prospective, randomised control trial evaluating the effect of Continuous Positive airway pressure (CPAP), the standard treatment for obstructive sleep apnea (OSA) versus control (diet and lifestyle advice) on dipping status and blood pressure parameters in 100 non-dipper normotensive patients with moderate to severe obstructive sleep apnea and without established cardiovascular or metabolic disease.


Eligibility Criteria:
Inclusion Criteria:

* Newly diagnosed moderate-severe OSA (by standard criteria)
* Absence of known hypertension and antihypertensive medication
* Office blood pressure \<140/90mmHg
* Age 18 - 70 years
* Able to provide written, informed consent

Exclusion Criteria:

* Pregnancy
* Previous diagnosis of OSA or previous CPAP treatment
* Diagnosis of Diabetes Mellitus
* Active treatment for malignancy or severe psychiatric disorder
* History of cardiovascular disease or cerebrovascular disease
* Moderate or severe chronic kidney disease (CKD) defined as a eGFR of ≤ 44mL/min/1.73m2
* Dipper on ABPM
* Morbid obesity, defined as BMI ≥40
* Professional drivers or drivers with a history of road-traffic accident due to sleepiness
* Severe excessive daytime sleepiness defined as Epworth sleepiness scale (ESS) \>15
Evaluation of the Subjectively Perceived Pelvic Floor Function in Patients With Gynecological Tumors and Breast Cancer Under Systemic Tumor Therapy Using a Validated Questionnaire

The multimodal therapy of gynecological malignancies and breast cancer often leads to an impairment of the pelvic floor function. This has a major impact on the quality of life of cancer patients. The aim of the study is to record and analyze the potential subjective impairment of the bladder, bowel and sexual function under systemic tumor therapy as well as possible influencing factors by means of validated disease-specific questionnaires. to find possible starting points for the prevention and treatment of the symptoms.


Eligibility Criteria:
Inclusion Criteria:

* Breastcancer under tumor therapy
* Gynecological carcinoma under tumor therapy

Exclusion Criteria:

* none